Mavragani CP - Search Results

1

TREX1 variants in Sjogren's syndrome related lymphomagenesis.

Nezos A, Makri P, Gandolfo S, De Vita S, Voulgarelis M, Crow MK, Mavragani CP. Nezos A, et al. Among authors: mavragani cp. Cytokine. 2020 Aug;132:154781. doi: 10.1016/j.cyto.2019.154781. Epub 2019 Jul 18. Cytokine. 2020. PMID: 31326279

2

Midfacial swelling and oro-nasal involvement in a 53-year-old patient with bilateral pulmonary infiltrations.

Mavragani CP, Paikos S, Doussis-Anagnostopoulou I, Voulgarelis M. Mavragani CP, et al. Clin Exp Rheumatol. 2001 Sep-Oct;19(5):577-81. Clin Exp Rheumatol. 2001. PMID: 11579720 No abstract available.

3

Central nervous system involvement in Sjogren's syndrome.

Soliotis FC, Mavragani CP, Moutsopoulos HM. Soliotis FC, et al. Among authors: mavragani cp. Ann Rheum Dis. 2004 Jun;63(6):616-20. doi: 10.1136/ard.2003.019497. Ann Rheum Dis. 2004. PMID: 15140765 Free PMC article. No abstract available.

4

Conventional therapy of Sjogren's syndrome.

Mavragani CP, Moutsopoulos HM. Mavragani CP, et al. Clin Rev Allergy Immunol. 2007 Jun;32(3):284-91. doi: 10.1007/s12016-007-8008-3. Clin Rev Allergy Immunol. 2007. PMID: 17992595 Review.

5

Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Mavragani CP, et al. Arthritis Rheum. 2007 Dec;56(12):3995-4004. doi: 10.1002/art.23062. Arthritis Rheum. 2007. PMID: 18050196 Free PMC article. Clinical Trial.

6

Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case-control study.

Karaiskos D, Mavragani CP, Makaroni S, Zinzaras E, Voulgarelis M, Rabavilas A, Moutsopoulos HM. Karaiskos D, et al. Among authors: mavragani cp. Ann Rheum Dis. 2009 Jan;68(1):40-6. doi: 10.1136/ard.2007.084152. Epub 2008 Feb 14. Ann Rheum Dis. 2009. PMID: 18276740

7

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Mavragani CP, La DT, Stohl W, Crow MK. Mavragani CP, et al. Arthritis Rheum. 2010 Feb;62(2):392-401. doi: 10.1002/art.27226. Arthritis Rheum. 2010. PMID: 20112385 Free PMC article. Clinical Trial.

8

Activation of type I interferon in systemic lupus erythematosus.

Kirou KA, Mavragani CP, Crow MK. Kirou KA, et al. Among authors: mavragani cp. Expert Rev Clin Immunol. 2007 Jul;3(4):579-88. doi: 10.1586/1744666X.3.4.579. Expert Rev Clin Immunol. 2007. PMID: 20477162

9

Activation of the type I interferon pathway in primary Sjogren's syndrome.

Mavragani CP, Crow MK. Mavragani CP, et al. J Autoimmun. 2010 Nov;35(3):225-31. doi: 10.1016/j.jaut.2010.06.012. Epub 2010 Jul 31. J Autoimmun. 2010. PMID: 20674271 Review.

10

Endocrine alterations in primary Sjogren's syndrome: an overview.

Mavragani CP, Fragoulis GE, Moutsopoulos HM. Mavragani CP, et al. J Autoimmun. 2012 Dec;39(4):354-8. doi: 10.1016/j.jaut.2012.05.011. Epub 2012 Jun 12. J Autoimmun. 2012. PMID: 22695186 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters